In vitro efficacy of newly designed vancomycin-based microparticles.
OBJECTIVE
To compare the in vitro bactericidal and anti-adhesion properties of vancomycin-based microparticles and lyophilized vancomycin and estimate their relevance to perioperative antibiotic prophylaxis and endophthalmitis prevention.


METHODS
University research laboratory, Lyon, France.


METHODS
The bactericidal and anti-adhesion properties of a newly designed drug-delivery system were assessed on Staphylococcus epidermidis clinical strain N890074 containing the intercellular adhesion locus ica. Lyophilized vancomycin at 20 mug/mL was used as a standard. The new drug-delivery system, designed for the study, consisted of sterile, biocompatible, and biodegradable microparticles with continuous release of vancomycin. To obtain bacterial killing and anti-adhesion curves, experiments were first performed in a bacterial suspension containing 1000 colony-forming units per milliliter. Experiments were then performed with intraocular lenses incubated in the suspension. Efficacy was investigated by bacterial counts and scanning electron microscopy observations.


RESULTS
The bactericidal and anti-adhesion effects of vancomycin-based microparticles started after 3 hours (P<.002) and 1 hour (P<.001), respectively, and of lyophilized vancomycin, after 1 hour (P = .004) and 1 hour (P<.001), respectively. There was no difference between the 2 forms of vancomycin in the bactericidal effect starting at 21 hours and the anti-adhesion effect starting at 6 hours (P>.05).


CONCLUSIONS
The newly designed vancomycin-based microparticles showed relevant antibacterial and anti-adhesion properties after releasing a sufficient antibacterial quantity, proving that vancomycin remains efficient after undergoing the encapsulation process.
Hachicha
Walid
W
Laboratoire d'Automatique et de Génie des Procédés, Villeurbanne, France. hachicha@lagep.cpe.fr
Fessi
Hatem
H
Casoli-Bergeron
Emmanuelle
E
Lee
Mi-Yeon
MY
Jaafar
Chiraz
C
Clayer-Montembault
Alexandra
A
Burillon
Carole
C
Freney
Jean
J
Kodjikian
Laurent
L
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019072:Antibiotic Prophylaxis; D001422:Bacterial Adhesion / Q000187:drug effects*; D001672:Biocompatible Materials; D015169:Colony Count, Microbial; D004337:Drug Carriers; D009877:Endophthalmitis / Q000517:prevention & control; D019344:Lactic Acid; D007910:Lenses, Intraocular / Q000382:microbiology*; D008855:Microscopy, Electron, Scanning; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000254:growth & development; D014640:Vancomycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D004337:Drug Carriers; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D014640:Vancomycin